NASDAQ:HLVX - Nasdaq - US43157M1027 - Common Stock - Currency: USD
1.85
0 (0%)
The current stock price of HLVX is 1.85 USD. In the past month the price increased by 14.91%. In the past year, price decreased by -85.54%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.12 | 329.14B | ||
AMGN | AMGEN INC | 14.17 | 150.99B | ||
GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
ARGX | ARGENX SE - ADR | 323.56 | 37.54B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
NTRA | NATERA INC | N/A | 20.79B | ||
BIIB | BIOGEN INC | 7.22 | 17.39B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The company went IPO on 2022-04-29. The firm's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The firm has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
HILLEVAX INC
321 Harrison Ave, Suite 500
Boston MASSACHUSETTS US
Employees: 90
Company Website: https://www.hillevax.com/
Investor Relations: https://ir.hillevax.com/
Phone: 16172135054
The current stock price of HLVX is 1.85 USD.
The exchange symbol of HILLEVAX INC is HLVX and it is listed on the Nasdaq exchange.
HLVX stock is listed on the Nasdaq exchange.
8 analysts have analysed HLVX and the average price target is 2.04 USD. This implies a price increase of 10.27% is expected in the next year compared to the current price of 1.85. Check the HILLEVAX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
HILLEVAX INC (HLVX) has a market capitalization of 92.76M USD. This makes HLVX a Micro Cap stock.
HILLEVAX INC (HLVX) currently has 90 employees.
HILLEVAX INC (HLVX) has a support level at 1.64 and a resistance level at 1.87. Check the full technical report for a detailed analysis of HLVX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HLVX does not pay a dividend.
HILLEVAX INC (HLVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3).
The outstanding short interest for HILLEVAX INC (HLVX) is 5.27% of its float. Check the ownership tab for more information on the HLVX short interest.
ChartMill assigns a technical rating of 3 / 10 to HLVX. When comparing the yearly performance of all stocks, HLVX is a bad performer in the overall market: 91.46% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to HLVX. No worries on liquidiy or solvency for HLVX as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months HLVX reported a non-GAAP Earnings per Share(EPS) of -3. The EPS increased by 1.32% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -76.43% | ||
ROE | -95.33% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 48% to HLVX. The Buy consensus is the average rating of analysts ratings from 8 analysts.